Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Illumina Announces Outcome of Its Patent Litigation Against Syntrix Biosystems, Inc.



  Illumina Announces Outcome of Its Patent Litigation Against Syntrix
  Biosystems, Inc.

Business Wire

SAN DIEGO -- March 14, 2013

Illumina, Inc. (NASDAQ: ILMN) today announced that a federal jury in Tacoma,
Washington found that Illumina’s BeadChip array product infringed U.S. Patent
No. 6,951, 682, asserted by Syntrix Biosystems, Inc. The federal jury ordered
Illumina to pay approximately $96 million in damages to Syntrix based on a
royalty rate of six percent for BeadChip products sold by Illumina from 2005
through May 2012. United States District Court Judge Benjamin H. Settle,
however, dismissed from the case claims that Illumina’s alleged infringement
was willful and that Illumina misappropriated Syntrix’s trade secrets. The
Syntrix patent expires on September 17, 2019.

Illumina continues to believe that Syntrix’s claims are without merit.
Illumina intends to file post-trial motions asking the court to vacate the
jury’s finding and to rule as a matter of law that the BeadChip does not
infringe Syntrix’s patent.

Jay Flatley, Illumina’s President and CEO, stated, “We strongly disagree with
this verdict and plan to appeal the present finding of infringement. In the
meantime, we will continue to sell the products that are the subject of this
suit and no damages will be payable to Syntrix until all appropriate appeals
have been taken, which may take a number of years.” Mr. Flatley continued,
“Our BeadChip products are based on Dr. David Walt’s technology that was
licensed from Tufts University when Illumina was founded in 1998. Like many
other companies, we respect the valid and enforceable intellectual property
rights of others. Consistent with our policy, we believe we acted properly
with respect to the Syntrix ‘682 patent. We continue to feel very strongly
about our position that Syntrix’s allegations are without merit and that,
ultimately, our position will be vindicated.”

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer
of life science tools and integrated systems for the analysis of genetic
variation and function. We provide innovative sequencing and array-based
solutions for genotyping, copy number variation analysis, methylation studies,
gene expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products accelerate
genetic analysis research and its application, paving the way for molecular
medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release may contain forward-looking statements that involve risks and
uncertainties. Important factors that could cause actual results to differ
materially from those in any forward-looking statements are detailed in our
filings with the Securities and Exchange Commission, including our most recent
filings on Forms 10-K and 10-Q, or in information disclosed in public
conference calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date of this
release.

Contact:

Illumina, Inc.
Investors:
Rebecca Chambers
Investor Relations
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple
Public Relations
858-882-6822
pr@illumina.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement